Short answer
Quest Diagnostics (DGX) filed its Q3 2025 10-Q quarterly report on Oct 21, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2.8B (up 13.2% year over year) with net income of $245M.
Q3 2025 key financials · XBRL
- Revenue
- $2.8B
- +13.2% YoY · +2.0% QoQ
- Net income
- $245M
- +8.4% YoY · −13.1% QoQ
- Operating margin
- 13.7%
- EPS (diluted)
- $2.16
- +8.5% YoY · −12.6% QoQ
Source: XBRL data from the Quest Diagnostics (DGX) Q3 2025 10-Q on SEC EDGAR. USD.
Quest Diagnostics Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.82B for Q3 2025, up 13.1% YoY from $2.49B; DIS revenues $2.76B, up 13.5% YoY from $2.43B
- Operating margin 13.7% vs 13.3% YoY; Operating income $386M, up 16.8% YoY from $330M
- Best segment DIS: revenue up 13.5% to $2.76B with 12.5% volume growth; Worst segment DS revenues down 1.0% to $61M
- Operating cash flow $563M, up $207M YoY; Capital expenditures $144M, up $38M YoY; cash and equivalents $432M vs $549M year-end 2024
- Management notes potential 50-60 bps revenue reduction by 2028 from new healthcare legislation; ongoing Invigorate cost savings program targeting 3% annual savings
Risk Factors
- No new or changed risk factors since 2024 10-K according to 10-Q filing
- Continued exposure to regulatory risks from healthcare compliance and reimbursement policy changes
- Operational risks from dependence on laboratory testing volume and reimbursement rates remain significant
- Competitive risks from evolving healthcare market and innovation pressure persist
- Financial risks related to liquidity and debt maturity remain stable with no material updates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Quest Diagnostics quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.